Ovarian Disease – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Ovarian Disease – Drugs In Development, 2024 report and make more profitable business decisions.
Ovarian disease is a term for various conditions that affect the ovaries, which are the female reproductive organs that produce eggs and hormones. The most common ovarian diseases include polycystic ovary syndrome (PCOS), a hormonal disorder that causes irregular periods, excess androgen, and multiple cysts on the ovaries. PCOS can affect fertility and increase the risk of diabetes and heart disease. Another is ovarian cysts, fluid-filled sacs that develop on or in the ovaries. Most ovarian cysts are harmless and go away on their own, but some can cause pain, bleeding, or rupture. Ovarian cysts can be caused by hormonal imbalances, endometriosis, pregnancy, or other factors. Ovarian cancer is a type of cancer that starts in the ovaries or the fallopian tubes. Ovarian cancer can spread to other organs and cause various symptoms, such as abdominal bloating, pelvic pain, weight loss, or abnormal bleeding. Ovarian cancer can be treated with surgery, chemotherapy, or targeted therapy. Ovarian germ cell tumors are a rare type of tumor that originates from the cells that produce eggs. Ovarian germ cell tumors can be benign or malignant and usually affect young women or girls. Ovarian germ cell tumors can cause hormonal changes, abdominal pain, or a palpable mass. Ovarian germ cell tumors can be treated with surgery, chemotherapy, or radiation therapy.
The Ovarian Disease drugs in development market research report provide comprehensive information on the therapeutics under development for Ovarian Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ovarian Disease and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Ovarian Disease | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 34 molecules, with 30 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Ovarian Disease therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Ovarian Disease pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Ovarian Disease treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Amaro Therapeutics IncArkay Therapeutics LLC
Asia Stem Cell Regenerative Pharmaceutical Co Ltd
Bayer AG
Besins Healthcare SA
BioRestorative Therapies Inc
Brigham and Women's Hospital
Celmatix Inc
CHA Biotech Co Ltd
Creative Medical Technology Holdings Inc
EffRx Pharmaceuticals SA
Exeltis Pharmaceuticals Holding SL
Exorphia Co Ltd
exRNA Therapeutics Ltd
Follitech AB
HBM Alpha Therapeutics Inc
iCELL Biotechnology Co Ltd
ImmuneCyte Inc
Jiangsu Hengrui Medicine Co Ltd
Livzon Pharmaceutical Group Co Ltd
Massachusetts General Hospital
Multipotent Stem Cell Regenerative Medicine Technology Guangzhou Co Ltd
Oviva Therapeutics Inc
Qurgen Inc
Shilpa Biologicals Pvt Ltd
Spruce Biosciences Inc
Tel Aviv University
VCANBIO Cell and Gene Engineering Corp Ltd
Vitti Labs LLC
Yale Cancer Center
YB Life Science LLC
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Ovarian Disease reports